the No-reflow in Diabetic Patients Treated With Primary Percutaneous Coronary Intervention (PCI) (NCT04835974) | Clinical Trial Compass
UnknownNot Applicable
the No-reflow in Diabetic Patients Treated With Primary Percutaneous Coronary Intervention (PCI)
120 participantsStarted 2021-05-01
Plain-language summary
1- to find metabolic factors that correlate with the development of no reflow phenomenon that may help prevent its occurrence .
Who can participate
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* diabetic patients with STEMI treated with primary PCI
Exclusion Criteria:
non diabetic . with selected PCI
* (1) a history of an unprotected left main artery with severe liver and kidney diseases or coronary artery bypass grafting .
(2) patients who had valvular disease or cardiomyopathy . (3) severe dissection, thromboembolism in other parts, or vasospasm; and known malignancy .
(4) patients with contraindications for anticoagulant therapy, such as active visceral hemorrhage, hemorrhagic stroke, or ischemic stroke within half a year (including transient ischemic attack), or aortic dissection, or patients with hematological diseases complicated with coagulation disorders .